NASDAQ:EOLSEvolus Stock Price, Forecast & News

Evolus' stock was trading at $5.91 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, EOLS shares have decreased by 44.8% and is now trading at $3.26.
View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Evolus.

Evolus is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020.
View our earnings forecast for Evolus.

Evolus will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Evolus Inc (NASDAQ:EOLS) posted its quarterly earnings results on Monday, May, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by $0.03. The firm had revenue of $10.50 million for the quarter, compared to the consensus estimate of $16.91 million. Evolus had a negative return on equity of 197.30% and a negative net margin of 217.51%.
View Evolus' earnings history.

8 brokers have issued 1-year price targets for Evolus' shares. Their forecasts range from $3.00 to $30.00. On average, they anticipate Evolus' share price to reach $11.88 in the next year. This suggests a possible upside of 264.3% from the stock's current price.
View analysts' price targets for Evolus.

News coverage about EOLS stock has trended negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Evolus earned a news impact score of -2.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Evolus.

Evolus saw a increase in short interest in June. As of June 30th, there was short interest totaling 5,000,000 shares, an increase of 14.7% from the June 15th total of 4,360,000 shares. Based on an average daily volume of 871,900 shares, the short-interest ratio is currently 5.7 days. Currently, 22.8% of the shares of the stock are sold short.
View Evolus' Current Options Chain.

Some companies that are related to Evolus include Syros Pharmaceuticals (SYRS), Protagonist Therapeutics (PTGX), Albireo Pharma (ALBO), BioDelivery Sciences International (BDSI), XBiotech (XBIT), Avid Bioservices (CDMO), Ocular Therapeutix (OCUL), BELLUS Health (BLUSF), Zafgen (ZFGN), Satsuma Pharmaceuticals (STSA), Puma Biotechnology (PBYI), Avedro (AVDR), Merus (MRUS), Kamada (KMDA) and Organogenesis (ORGO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Canopy Growth (CGC), Tandem Diabetes Care (TNDM), Calithera Biosciences (CALA) and JD.Com (JD).

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include UBS Group AG (0.19%). Company insiders that own Evolus stock include Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Rui Avelar, Simone Blank and Vikram Malik.
View institutional ownership trends for Evolus.

EOLS stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have bought Evolus stock in the last two years include David N Gill, Kristine Romine, Michael M Jafar, Simone Blank, and Vikram Malik.
View insider buying and selling activity for Evolus.

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EOLS stock can currently be purchased for approximately $3.26.

Evolus has a market capitalization of $109.96 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis. Evolus employs 70 workers across the globe.

The official website for Evolus is www.evolus.com.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]